Previous 10 | Next 10 |
Halvorsen's 13F portfolio value decreased from $36.04B to $34.49B this quarter. The number of positions increased from 96 to 107. Viking Global added Twilio, Workday, and Aon plc while dropping Fidelity National Information Services and Snowflake. The top three positions are Ginkg...
Phase 2 data from a trial of patients with limb-girdle muscular dystrophy type 2i (LGMD2i) treated with BridgeBio's (NASDAQ:BBIO) BBP-418 found that it may be able to treat the root cause of the disease. Results found that participants had an average 43% increase in the ratio of glycosylated ...
- 43% increase in the ratio of glycosylated alpha-dystroglycan (αDG) to total αDG from baseline were measured across all three dosing cohorts, signifying the oral therapy has the potential to address both the root cause of LGMD2i and drive functional improvements for pa...
PALO ALTO, Calif., March 11, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that it will host an investor ...
BridgeBio Pharma (NASDAQ:BBIO), a commercial-stage biotech company focused on genetic diseases, announced an agreement with Sentynl Therapeutics to sell its global rights for Nulibry (Fosdenopterin), one of the two licensed products of the company. Nulibry injection is the first and only ther...
PALO ALTO and SOLANA BEACH, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company that focuses on genetic diseases and cancers, and Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical ...
This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. After the Q4-2021 13F filings the consensus holdings were updated, 7 stocks were removed and 7 added from the unive...
The following slide deck was published by BridgeBio Pharma, Inc. in conjunction with this event. For further details see: BridgeBio Pharma (BBIO) Presents At Global Healthcare Virtual Conference - Slideshow
BridgeBio Pharma press release (NASDAQ:BBIO): Q4 GAAP EPS of -$1.01 misses by $0.16. Revenue of $12.89M (+10641.7% Y/Y) misses by $8.69M. Shares -4.5% PM. For further details see: BridgeBio Pharma GAAP EPS of -$1.01 misses by $0.16, revenue of $12.89M misses by $8.69M
–Secured up to $750 million in non-dilutive debt financing in November 2021, extending BridgeBio’s financial runway into 2024 –Dosed first patient in Phase 1/2 trial of investigational gene therapy for congenital adrenal hyperplasia (CAH); initial data reado...
News, Short Squeeze, Breakout and More Instantly...
PALO ALTO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, announced that Thomas Trimarchi, Ph.D., has been appointed President and...
2024-07-09 22:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-20 00:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...